Irsenontrine (maleate)

Irsenontrine (E2027) maleate is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine maleate can be used for the research of neurological diseases[1][2].

Product Specifications

CAS Number

[1630083-70-3]

Product Name Alternative

E2027 (maleate)

UNSPSC

12352005

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/irsenontrine-maleate.html

Solubility

10 mM in DMSO

Smiles

O=C1NC2=C(C=CC(C3=C(C)C(OC)=NC=C3C)=C2)C4=C1C=NN4[C@@H]5COCC5.O=C(O)/C=C\C(O)=O

Molecular Formula

C26H26N4O7

Molecular Weight

506.51

References & Citations

[1]Miyamoto, et al. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine. WO2018221550 A1|[2]Hershey LA, et al. Pharmacological Management of Dementia with Lewy Bodies. Drugs Aging. 2019;36 (4) :309-319.|[3]Eisai to present latest research on Alzheimer’s disease / dementia pipeline at the 14th international conference on Alzheimer’s & Parkinson’s diseases